Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Change in Receivables (2023 - 2025)

BioXcel Therapeutics (BTAI) has 3 years of Change in Receivables data on record, last reported at -$17000.0 in Q3 2025.

  • For Q3 2025, Change in Receivables rose 97.9% year-over-year to -$17000.0; the TTM value through Sep 2025 reached -$3000.0, up 99.59%, while the annual FY2024 figure was $60000.0, 133.9% up from the prior year.
  • Change in Receivables reached -$17000.0 in Q3 2025 per BTAI's latest filing, down from $17000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $434000.0 in Q2 2024 and bottomed at -$809000.0 in Q3 2024.
  • Average Change in Receivables over 3 years is -$22545.5, with a median of $35000.0 recorded in 2023.
  • The widest YoY moves for Change in Receivables: up 777.14% in 2024, down 366.12% in 2024.
  • A 3-year view of Change in Receivables shows it stood at -$664000.0 in 2023, then surged by 119.28% to $128000.0 in 2024, then crashed by 113.28% to -$17000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$17000.0 in Q3 2025, $17000.0 in Q2 2025, and -$131000.0 in Q1 2025.